Summary
Serratia marcescens is a gram-negative bacillus that is an opportunistic agent in respiratory tract infections, urinary tract infections, and septicemia. It is rarely also a cause of infective endocarditis which follows a rapid and devastating course, typically in persons with history of intravenous drug use (IDU). This article reports a fatal case of a 27-year-old patient with a known history of IDU, who presented with clinical symptoms concerning right-sided endocarditis as well as signs of acute respiratory distress syndrome. Finally, a detailed review of the literature is provided concerning the acute endocarditis of a tricuspid valve, especially associated with Serratia marcescens infection.
References
Hubers SA, DeSimone DC, Gersh BJ, Anavekar NS. Infective endocarditis: A contemporary review. Mayo Clin Proc. 2020;95(5):982–97.
Rudasill SE, Sanaiha Y, Mardock AL, et al. Clinical outcomes of infective endocarditis in injection drug users. j Am Coll Cardiol. 2019;73(5):559–70.
Cristina ML, Sartini M, Spagnolo AM. Serratia marcescens infections in Neonatal Intensive Care Units (NICUs). Int J Environ Res Public Health. 2019;16(4):610.
Wheat RP, Zuckerman A, Rantz LA. Infection due to chromobacteria; report of 11 cases. AMA Arch Intern Med. 1951;88(4):461–6.
Hou J, Mao D, Zhang Y, et al. Long-term spatiotemporal variation of antimicrobial resistance genes within the Serratia marcescens population and transmission of S. marcescens revealed by public whole-genome datasets. J Hazard Mater. 2022;423(Pt B):127220.
Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of non-HACEK infective endocarditis in the southeast United States. plos One. 2020;15(3):e230199.
Luttmann K, Starnes VR, Haddad M, Duggan J. Serratia marcescens, a rare and devastating cause of endocarditis: A case report and review of the literature. Cureus. 2022;14(6):e25572.
Clarelin A, Rasmussen M, Olaison L, Ragnarsson S. Comparing right- and left sided injection-drug related infective endocarditis. Sci Rep. 2021;11(1):1177.
Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000;30(2):374–9.
Libby P, Bonow RO, Mann DL, et al. Braunwald’s heart disease—A textbook of cardiovascular medicine. 12th ed. Amsterdam: Elsevier; 2021. p. 2034. ISBN 978-0-323-72219‑3.
Cuervo G, Escrihuela-Vidal F, Gudiol C, Carratalà J. Current challenges in the management of infective Endocarditis. Front Med (lausanne). 2021;8:641243.
Rodger L, Shah M, Shojaei E, Hosseini S, Koivu S, Silverman M. Recurrent endocarditis in persons who inject drugs. Open Forum Infect Dis. 2019;6(10):ofz396.
Luttmann K, Starnes VR, Haddad M, Duggan J. Serratia marcescens, a rare and devastating cause of Endocarditis: A case report and review of the literature. Cureus. 2022;14(6):e25572.
Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128.
Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–86.
Sordelli C, Fele N, Mocerino R, et al. Infective endocarditis: Echocardiographic imaging and new imaging modalities. J Cardiovasc Echogr. 2019;29(4):149–55.
Otto CM, Nishimura RA, Bonow RO, et al. ACC/AHA Guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;143(5):e35–e71.
Falcone M, Tiseo G, Durante-Mangoni E, et al. Risk factors and outcomes of endocarditis due to Non-HACEK gram-negative bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. Antimicrob Agents Chemother. 2018;62(4):e2208–17.
Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ. Antibacterial Resistance Leadership Group. A primer on AmpC β‑Lactamases: Necessary knowledge for an increasingly multidrug-resistant world. Clin Infect Dis. 2019;69(8):1446–55.
Ahmed T, Safdar A. Ethical Dilemma: Should continuous intravenous drug use affect appropriate management in prosthetic valve endocarditis? Cureus. 2020;12(6):e8458.
Acknowledgements
The authors would like to acknowledge the laboratory technicians and support staff for their timely effort, sincerity, and dedication towards work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
T. Poruban, M. Hunavy, D. Farkas, S. Carnoky and M. Jakubova declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Poruban, T., Hunavy, M., Farkas, D. et al. A rare Serratia marcescens-associated acute endocarditis of a tricuspid valve in an intravenous drug user. Wien Klin Wochenschr 135, 631–636 (2023). https://doi.org/10.1007/s00508-023-02217-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-023-02217-0